Page last updated: 2024-11-13

4-hydroxy-6-methyl-2-pyrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxy-6-methyl-2-pyrone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54675757
CHEMBL ID54907
CHEBI ID16458
SCHEMBL ID320025
SCHEMBL ID918518
MeSH IDM0516625

Synonyms (100)

Synonym
unii-s1s883s4ee
s1s883s4ee ,
BRD-K77202630-001-02-9
4-hydroxy-6-methyl-2h-pyran-2-one
CHEBI:16458 ,
2h-pyran-2-one, 4-hydroxy-6-methyl-
triacetic acid lactone
nsc34625
nsc-34625
DIVK1C_006912
SDCCGMLS-0066925.P001
SPECTRUM4_001907
SPECTRUM_001904
BSPBIO_003340
nsc 34625
6-methyl-4-hydroxypyron-(2)
einecs 211-619-2
4-hydroxy-6-methylpyran-4-one
brn 0113815
ccris 3600
SPECTRUM5_000594
675-10-5
4-hydroxy-6-methyl-2-pyrone
triacetate lactone
C02752
4-hydroxy-6-methyl-2-pyrone, 98%
NCGC00095976-01
KBIO2_005000
KBIO1_001856
KBIO2_007568
KBIOSS_002438
KBIO3_002560
KBIO2_002432
KBIOGR_002500
SPECPLUS_000816
SPBIO_002135
SPECTRUM2_001978
SPECTRUM3_001720
SPECTRUM1600759
NCGC00178130-01
inchi=1/c6h6o3/c1-4-2-5(7)3-6(8)9-4/h2-3,7h,1h
CHEMBL54907 ,
4-hydroxy-6-methylpyran-2-one
3,5-dihydroxysorbic acid delta-lactone
H0715
AKOS000119605
NCGC00095976-02
6-methyl-4-hydroxy-2-pyrone
2-hydroxy-6-methyl-4h-pyran-4-one
70254-61-4
AKOS016007260
CCG-39516
bdbm50405204
FT-0618665
4-hydroxy-6-methyl-.alpha.-pyrone
sorbic acid, 3,5-dihydroxy-, .delta.-lactone
SCHEMBL320025
7H-939
4-hydroxy-6-methylpyranone
4-hydroxy-6 -methyl-2-pyrone
6-methyl-4-hydroxy pyran-2-one
6-methyl-4-hydroxypyran-2-one
4-hydroxy-6-methyl-pyran-2-one
4-hydroxy-6-methyl-pyrone
6-methyl-4-hydroxypyrone
OOKCZXGEYPSNIM-UHFFFAOYSA-N
4-hydroxy-6-methyl pyranone
4- hydoxy-6-methyl-2-pyrone
4-hydroxy-6-methyl pyr-2-one
4-hydroxy-6-methylpyrone
4-hydroxy- 6-methyl-2-pyrone
4-hydoxy-6-methyl-2-pyrone
DTXSID1060974
SCHEMBL918518
W-104713
CS-W020045
AC-27196
mfcd00006641
F0001-1779
3,5-dihydroxysorbic acid d-lactone
4h-pyran-4-one, 2-hydroxy-6-methyl-
SR-05000002374-1
sr-05000002374
SY001948
F14831
mfcd18820248
FT-0715301
Q7839869
AMY23278
BRD-K77202630-001-03-7
O10801
CS-0061284
A866649
kj6 ,
6-methyl-4-oxidanyl-pyran-2-one
EN300-20217
PD000450
HY-Y1634
SY105730
Z104477314
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-pyranonesA pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alpha-galactosidaseHomo sapiens (human)Potency0.79434.466818.391635.4813AID2107
DNA polymerase kappa isoform 1Homo sapiens (human)Potency35.48130.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neutrophil elastaseHomo sapiens (human)Ki8,128.31010.00201.28669.5499AID66470
Chymotrypsin-CHomo sapiens (human)Ki6,309.56980.00100.92403.7000AID52466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
intracellular calcium ion homeostasisChymotrypsin-CHomo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
protein bindingChymotrypsin-CHomo sapiens (human)
peptidase activityChymotrypsin-CHomo sapiens (human)
serine-type endopeptidase activityChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID715795Induction of apoptosis in human U937 cells assessed as reduction of normal cells at 500 uM after 24 hrs by Annexin V-FITC double staining2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1101274Antifungal activity against Sclerotium delphinii assessed as fungal growth inhibition at 100 ppm relative to untreated control2001Bioscience, biotechnology, and biochemistry, Jan, Volume: 65, Issue:1
Syntheses and biological activities of pyranyl-substituted cinnamates.
AID1865413Inhibition of full length recombinant C-terminal FLAG-tagged human HDAC2 expressed in baculovirus-infected Sf9 cells at 1 mM measured for 2 hrs by fluorescence-based assay relative to control2022ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10
Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
AID1101273Antifungal activity against Rhizoctonia solani assessed as fungal growth inhibition at 100 ppm relative to untreated control2001Bioscience, biotechnology, and biochemistry, Jan, Volume: 65, Issue:1
Syntheses and biological activities of pyranyl-substituted cinnamates.
AID1754626Inhibition of Wnt signalling in HEK293 cells harbouring TCF/beta-catenin luciferase reporter gene assessed as TCF/beta-catenin transcriptional activity at 30 to 60 uM by TOPFlash luciferase assay2021Bioorganic & medicinal chemistry letters, 08-01, Volume: 45Linderapyrone: A Wnt signal inhibitor isolated from Lindera umbellata.
AID715776Pro-oxidant activity in 0.1 M potassium phosphate buffer at pH 7.4 assessed as increase of oxidation potential by cyclic voltammetry analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715803Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715802Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715783Induction of cell differentiation in human U937 cells assessed as increase of CD11b and CD14 expression at 500 uM after 72 hrs by FACS flow cytometer analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID19471Partition coefficient (logP) (octanol/saline)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID156214Inhibitory activity against porcine pancreatic elastase (PP elastase) expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID52466Inhibitory activity against bovine Chymotrypsinogen expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID66470Inhibitory activity against human leukocyte elastase (HL elastase) expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (8.70)18.7374
1990's2 (4.35)18.2507
2000's5 (10.87)29.6817
2010's21 (45.65)24.3611
2020's14 (30.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.86 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]